KLOW Blend --- Research Product Overview

**Disclaimer:** This article is provided for educational and research purposes only. The KLOW research blend sold by Viking Labs is intended for laboratory research use only. None of its component peptides are approved by the FDA for human therapeutic use, and nothing in this article constitutes medical advice or a recommendation for self-administration.

Overview

The KLOW blend is a co-formulated lyophilized research peptide presentation that combines four research peptides commonly studied in tissue-repair and immunomodulation models: GHK-Cu (typically 50 mg), BPC-157 (typically 10 mg), TB-500 (a synthetic thymosin beta-4 analogue, typically 10 mg), and KPV (a tripeptide derived from alpha-MSH, typically 10 mg). The total peptide content of a typical KLOW vial is approximately 80 mg. The exact mass per component on a given Viking Labs vial is reported on the lot-specific certificate of analysis.

The "KLOW" designation is widely used across the research peptide marketplace to refer to this specific four-peptide combination. It is not a single chemical entity; rather, it is a research convenience formulation that allows investigators to study the simultaneous pharmacology of four distinct repair-related peptides in a single dosing solution. For background on the underlying biology of each component, the BPC-157 mechanisms article and the BPC-157 vs. TB-500 comparison are useful entry points.

For deep dives into each individual peptide's biology, see the linked single-peptide research articles below.

Sequence and Structural Notes

The blend's components are structurally diverse:

• GHK-Cu --- glycyl-L-histidyl-L-lysine tripeptide complexed with copper(II); ~340 Da peptide + Cu2+
• BPC-157 --- pentadecapeptide from human gastric juice (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val); ~1419 Da
• TB-500 (thymosin beta-4 / fragment analogue) --- 43-amino-acid peptide; ~4921 Da; some preparations use a key active fragment rather than the full TB4 sequence
• KPV --- lysine-proline-valine tripeptide derived from the C-terminus of alpha-melanocyte-stimulating hormone; ~342 Da

This structural heterogeneity is the source of both the blend's research utility and its formulation challenges (different solubility, different stability profiles).

Mechanism of Action

The four peptides act through distinct molecular pathways that are commonly studied in parallel because they converge on tissue-repair and immunomodulatory phenotypes:

• GHK-Cu: copper-binding tripeptide that modulates extracellular matrix gene expression, promotes wound healing, and exhibits antioxidant properties; copper-dependent gene-expression effects across thousands of transcripts have been mapped (Pickart et al., 2015).
• BPC-157: pentadecapeptide with broad cytoprotective and angiogenic effects, including FAK-paxillin pathway activation, NO-system modulation, and VEGF-mediated angiogenesis. See the BPC-157 mechanisms article and our companion piece on nitric oxide peptides for relevant pathway context.
• TB-500 / thymosin beta-4: 43-aa peptide with G-actin sequestration, ILK/Akt-mediated cell migration, and pro-angiogenic activity (see the TB-500 product overview).
• KPV: alpha-MSH-derived tripeptide with anti-inflammatory effects via NF-kB modulation in epithelial and immune cells (Brzoska et al., 2008; Kannengiesser et al., 2008). See the KPV product overview for detail.

The research interest in the combination is mechanistic complementarity: GHK-Cu drives extracellular matrix gene expression, BPC-157 and TB-500 drive cell-migration and angiogenesis, and KPV provides anti-inflammatory tone --- four non-overlapping pathways that researchers may study in parallel in tissue-repair models.

Comparator Peptides --- KLOW vs. Other Multi-Component Repair Blends

KLOW occupies a specific niche in the research peptide marketplace: a four-component repair blend balancing matrix, angiogenesis, and immunomodulation pathways. Several alternative blend designs are studied in parallel.

KLOW vs. BPC-157 + TB-500 alone. The most common simpler blend is BPC-157 paired with TB-500, which captures the angiogenesis and cell-migration components of KLOW but lacks the matrix-gene-expression layer (GHK-Cu) and the anti-inflammatory tone (KPV). Our BPC-157 vs. TB-500 and BPC-157 vs. TB-500 comparison articles cover the dual-blend profile in detail.

KLOW vs. GHK-Cu + matrix peptide blends. Some researchers pair GHK-Cu with thymosin alpha-1 (thymosin alpha overview) for matrix-plus-immune-modulation profiles distinct from KLOW; the choice depends on whether T-cell or epithelial NF-kB inhibition is the priority anti-inflammatory mechanism.

KLOW vs. four-peptide longevity blends. A separate class of blends combines Epitalon, FOXO4-DRI, NAD+, and a senolytic candidate for senescence-targeted research. KLOW is not a substitute for these blends; the mechanistic targets are largely non-overlapping.

Per-component potency comparison. Within KLOW, GHK-Cu drives the largest mass fraction (62.5% at the typical 50:10:10:10 ratio) and the broadest transcriptional footprint. BPC-157 and TB-500 contribute roughly equally to angiogenesis and migration. KPV's mass fraction is small but its tripeptide pharmacology is potent in epithelial NF-kB assays.

Deeper Preclinical Breakdown

The blend itself has limited dedicated preclinical literature; the evidence base is built from the individual components.

Pickart et al. (2015) --- GHK-Cu transcriptional footprint (BioMed Res Int). Methodology: cultured human dermal fibroblasts treated with GHK-Cu at 1 nM for 24 hours, with whole-transcriptome microarray. Key result: GHK-Cu upregulated approximately 4,200 genes and downregulated approximately 4,000 genes (greater than 1.5-fold change), with significant enrichment for ECM remodeling, antioxidant defense, and DNA repair pathways. Limitation: in vitro only; in vivo translation of the transcriptional signature is incomplete.

Sikiric et al. (2018) --- BPC-157 in tendon and ligament repair models. Methodology: rat Achilles transection and MCL injury models; BPC-157 administered intraperitoneally or via local injection at 10 ng-microgram/kg ranges. Key result: dose-dependent acceleration of tendon and ligament repair, with measurable increases in fibroblast migration and collagen organization. Limitation: most studies use surrogate histological endpoints; functional biomechanical recovery is reported less consistently. See BPC-157 mechanisms for full detail.

Kannengiesser et al. (2008) --- KPV in DSS colitis (Inflamm Bowel Dis, PMID 18308828 / 18275074). Methodology: BALB/c mice with DSS-induced colitis received KPV at 0.1-10 mg/kg/day orally for 7 days. Key result: dose-dependent reduction in colitis severity score, mucosal cytokine load (TNF-alpha, IL-1-beta), and NF-kB activation in colonic epithelial cells. Limitation: oral bioavailability of KPV is incompletely characterized; the route-of-administration translation requires care.

Preclinical Research Summary

Each component has its own substantial preclinical literature, summarized in the corresponding single-peptide articles. Direct preclinical studies of the four-component blend specifically (as a single formulation) are limited; most experimental data is generated by treating animals or cell cultures with the individual components or pairwise combinations. The blend is therefore most useful as a convenient co-formulation for hypothesis-generating studies and as a research tool for investigators studying the convergence of distinct repair pathways.

Common Research Applications

• Wound healing models (skin punch biopsy, splinted excisional wounds)
• Tendon and ligament repair models (Achilles transection, MCL injury)
• Inflammatory bowel disease models (TNBS, DSS colitis)
• Skin inflammation and barrier-function research
• Cell-culture studies of fibroblast migration, proliferation, and ECM gene expression
• Comparative studies versus individual components

Formulation Considerations

KLOW's structural heterogeneity creates real formulation challenges. The four peptides differ in solubility, isoelectric point, and degradation kinetics; the blend's overall properties are bounded by the most demanding component.

Diluent. Sterile bacteriostatic water is the standard diluent; sterile saline is acceptable but PBS is preferred over Tris or HEPES because GHK-Cu is the most chelation-sensitive component. Strongly chelating buffers (high-EDTA, high-citrate) will strip Cu2+ from the GHK-Cu complex, abolishing its activity. The reconstituted solution is characteristically blue from the GHK-Cu(II) chromophore; this is expected and is not a degradation signal.

Lyophilization and [reconstitution](/research/peptide-reconstitution-guide). The four-component cake reconstitutes within minutes with gentle inversion; vortexing is discouraged because TB-500 is mildly surface-active and prone to foaming. Working concentrations are typically 1-5 mg/mL of the most abundant component (GHK-Cu), with the others scaled by mass ratio.

Stability profiles. TB-500 is the least solution-stable component (greater than 95% main-peak purity for 7-14 days at 2-8 degrees C). BPC-157 is the most stable (28-42 days). GHK-Cu is stable so long as Cu2+ is retained on the peptide. KPV is stable for the longest period due to its tripeptide simplicity. The blend's overall in-solution shelf life is therefore typically 14-21 days, bounded by TB-500.

Common [COA](/research/glossary#coa) impurities. Per-component impurities should be reported individually: GHK-Cu (apo-GHK fraction, copper content by ICP-MS), BPC-157 (truncation at Pro4-Pro5), TB-500 (oxidized Met variants), KPV (acetate counterion). See our reading HPLC COA reference.

Research-Context Dosing Ranges

In published preclinical literature, the individual components have been studied at the following preclinical dose ranges: GHK-Cu at 0.1-10 mg/kg subcutaneously or intraperitoneally; BPC-157 at 10 ng/kg to 10 microgram/kg intraperitoneally or per os; TB-500 at 0.1-1 mg/kg intraperitoneally; KPV at 0.1-10 mg/kg per os or intraperitoneally. The blend has been used in some research workflows at proportional doses determined by the lot-specific mass ratio. These dose ranges are references to the published rodent literature only and are not recommendations for human use.

Handling, Reconstitution, and Storage

The blend should be stored as a lyophilized solid at -20 degrees C protected from light. Reconstitute with sterile bacteriostatic water; the working concentration depends on the lot-specific component masses (consult the COA). Once reconstituted, store at 2-8 degrees C and use within approximately 14-21 days based on buffer and aseptic technique.

GHK-Cu in solution gives the blend a characteristic blue color due to the copper(II) complex --- this is expected and does not indicate degradation. The presence of Cu2+ does, however, mean that strongly chelating buffers (high-EDTA, high-citrate) are not appropriate for working stocks of the blend, as they may strip copper from GHK. Plain bacteriostatic water or PBS without strong chelators is preferred.

Different components have different stability profiles, so the blend's overall in-solution shelf life is bounded by the least stable component (typically TB-500 in solution). Avoid repeated freeze-thaw cycles. See our peptide reconstitution guide for general principles.

HPLC Purity and Lab Specifications

For each component:

• HPLC purity: greater than or equal to 98.0% (RP-HPLC, 214 nm) for each peptide identity
• Mass identity confirmation by ESI-MS or MALDI-TOF for each component
• Component mass ratio (e.g., 50:10:10:10 mg) reported on the COA
• Endotoxin: less than 5 EU/mg total peptide content
• Copper content for GHK-Cu component reported by ICP-MS or atomic absorption

For COA interpretation, see How to read a peptide COA.

Cross-References --- Related Viking Labs Research

• BPC-157 mechanisms
• BPC-157 vs. TB-500 comparison
• BPC-157 product overview
• TB-500 product overview
• GHK-Cu product overview
• KPV product overview
• Bacteriostatic water reference

*Provided for laboratory research purposes only. Not for human or veterinary use.*